Anti-BNLF2b antibody for accurate diagnosis of nasopharyngeal carcinoma: a prospective comparative study.
A new blood test for nasopharyngeal cancer detects the disease as accurately as existing tests, potentially improving screening in high-risk regions.
This prospective comparative study evaluated anti-BNLF2b antibody as a novel EBV-specific serum biomarker for NPC diagnosis versus established anti-VCA and anti-EBNA markers. The antibody showed superior or equivalent diagnostic performance, offering potential as an accessible screening tool in NPC-endemic regions.
What the study was
- Study design
- Prospective comparative study
- Category
- Other
- Maturity
- Validated
- Journal
- BMC Cancer
Why it surfaced
Prospective biomarker validation for NPC liquid diagnosis; directly relevant to early cancer detection watchlist; NPC has high unmet need for non-invasive diagnosis especially in Southeast Asian/East Asian populations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.